Liver cancer survival in the United States by race and stage (2001-2009)

Findings from the CONCORD-2 study

Behnoosh R. Momin, Paulo Pinheiro, Helena Carreira, Chunyu Li, Hannah K. Weir

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

BACKGROUND: Worldwide, liver cancer is a leading cause of death for both men and women. The number of Americans who are diagnosed with and die of liver cancer has been rising slowly each year. Using data from the CONCORD-2 study, this study examined population-based survival by state, race, and stage at diagnosis. METHODS: Data from 37 statewide registries, which covered 81% of the US population, for patients diagnosed during 2001-2009 were analyzed. Survival up to 5 years was adjusted for background mortality (net survival) with state- and race-specific life tables, and it was age-standardized with the International Cancer Survival Standard weights. RESULTS: Liver cancer was diagnosed overall more often at the localized stage, with blacks being more often diagnosed at distant and regional stages than whites. 5-year net survival was 12.2% in 2001-2003 and 14.8% in 2004-2009. Whites had higher survival than blacks in both calendar periods (11.7% vs 9.1% and 14.3% vs 11.4%, respectively). During 2004-2009, 5-year survival was 25.7% for localized-stage disease, 9.5% for regional-stage disease, and 3.5% for distant-stage disease. CONCLUSIONS: Some progress has occurred in survival for patients with liver cancer, but 5-year survival remains low, even for those diagnosed at the localized stage. Efforts directed at controlling well-established risk factors such as hepatitis B may have the greatest impact on reducing the burden of liver cancer in the United States. Cancer 2017;123:5059-78. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Original languageEnglish (US)
Pages (from-to)5059-5078
Number of pages20
JournalCancer
Volume123
DOIs
StatePublished - Dec 15 2017
Externally publishedYes

Fingerprint

Liver Neoplasms
Survival
Life Tables
Public Sector
Hepatitis B
Population
Registries
Cause of Death
Neoplasms
Weights and Measures
Mortality

Keywords

  • cancer registries
  • hepatitis
  • liver
  • population-based survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Liver cancer survival in the United States by race and stage (2001-2009) : Findings from the CONCORD-2 study. / Momin, Behnoosh R.; Pinheiro, Paulo; Carreira, Helena; Li, Chunyu; Weir, Hannah K.

In: Cancer, Vol. 123, 15.12.2017, p. 5059-5078.

Research output: Contribution to journalArticle

Momin, Behnoosh R. ; Pinheiro, Paulo ; Carreira, Helena ; Li, Chunyu ; Weir, Hannah K. / Liver cancer survival in the United States by race and stage (2001-2009) : Findings from the CONCORD-2 study. In: Cancer. 2017 ; Vol. 123. pp. 5059-5078.
@article{8c2a000de9ad40aab3dac929a7b75003,
title = "Liver cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study",
abstract = "BACKGROUND: Worldwide, liver cancer is a leading cause of death for both men and women. The number of Americans who are diagnosed with and die of liver cancer has been rising slowly each year. Using data from the CONCORD-2 study, this study examined population-based survival by state, race, and stage at diagnosis. METHODS: Data from 37 statewide registries, which covered 81{\%} of the US population, for patients diagnosed during 2001-2009 were analyzed. Survival up to 5 years was adjusted for background mortality (net survival) with state- and race-specific life tables, and it was age-standardized with the International Cancer Survival Standard weights. RESULTS: Liver cancer was diagnosed overall more often at the localized stage, with blacks being more often diagnosed at distant and regional stages than whites. 5-year net survival was 12.2{\%} in 2001-2003 and 14.8{\%} in 2004-2009. Whites had higher survival than blacks in both calendar periods (11.7{\%} vs 9.1{\%} and 14.3{\%} vs 11.4{\%}, respectively). During 2004-2009, 5-year survival was 25.7{\%} for localized-stage disease, 9.5{\%} for regional-stage disease, and 3.5{\%} for distant-stage disease. CONCLUSIONS: Some progress has occurred in survival for patients with liver cancer, but 5-year survival remains low, even for those diagnosed at the localized stage. Efforts directed at controlling well-established risk factors such as hepatitis B may have the greatest impact on reducing the burden of liver cancer in the United States. Cancer 2017;123:5059-78. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.",
keywords = "cancer registries, hepatitis, liver, population-based survival",
author = "Momin, {Behnoosh R.} and Paulo Pinheiro and Helena Carreira and Chunyu Li and Weir, {Hannah K.}",
year = "2017",
month = "12",
day = "15",
doi = "10.1002/cncr.30820",
language = "English (US)",
volume = "123",
pages = "5059--5078",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Liver cancer survival in the United States by race and stage (2001-2009)

T2 - Findings from the CONCORD-2 study

AU - Momin, Behnoosh R.

AU - Pinheiro, Paulo

AU - Carreira, Helena

AU - Li, Chunyu

AU - Weir, Hannah K.

PY - 2017/12/15

Y1 - 2017/12/15

N2 - BACKGROUND: Worldwide, liver cancer is a leading cause of death for both men and women. The number of Americans who are diagnosed with and die of liver cancer has been rising slowly each year. Using data from the CONCORD-2 study, this study examined population-based survival by state, race, and stage at diagnosis. METHODS: Data from 37 statewide registries, which covered 81% of the US population, for patients diagnosed during 2001-2009 were analyzed. Survival up to 5 years was adjusted for background mortality (net survival) with state- and race-specific life tables, and it was age-standardized with the International Cancer Survival Standard weights. RESULTS: Liver cancer was diagnosed overall more often at the localized stage, with blacks being more often diagnosed at distant and regional stages than whites. 5-year net survival was 12.2% in 2001-2003 and 14.8% in 2004-2009. Whites had higher survival than blacks in both calendar periods (11.7% vs 9.1% and 14.3% vs 11.4%, respectively). During 2004-2009, 5-year survival was 25.7% for localized-stage disease, 9.5% for regional-stage disease, and 3.5% for distant-stage disease. CONCLUSIONS: Some progress has occurred in survival for patients with liver cancer, but 5-year survival remains low, even for those diagnosed at the localized stage. Efforts directed at controlling well-established risk factors such as hepatitis B may have the greatest impact on reducing the burden of liver cancer in the United States. Cancer 2017;123:5059-78. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

AB - BACKGROUND: Worldwide, liver cancer is a leading cause of death for both men and women. The number of Americans who are diagnosed with and die of liver cancer has been rising slowly each year. Using data from the CONCORD-2 study, this study examined population-based survival by state, race, and stage at diagnosis. METHODS: Data from 37 statewide registries, which covered 81% of the US population, for patients diagnosed during 2001-2009 were analyzed. Survival up to 5 years was adjusted for background mortality (net survival) with state- and race-specific life tables, and it was age-standardized with the International Cancer Survival Standard weights. RESULTS: Liver cancer was diagnosed overall more often at the localized stage, with blacks being more often diagnosed at distant and regional stages than whites. 5-year net survival was 12.2% in 2001-2003 and 14.8% in 2004-2009. Whites had higher survival than blacks in both calendar periods (11.7% vs 9.1% and 14.3% vs 11.4%, respectively). During 2004-2009, 5-year survival was 25.7% for localized-stage disease, 9.5% for regional-stage disease, and 3.5% for distant-stage disease. CONCLUSIONS: Some progress has occurred in survival for patients with liver cancer, but 5-year survival remains low, even for those diagnosed at the localized stage. Efforts directed at controlling well-established risk factors such as hepatitis B may have the greatest impact on reducing the burden of liver cancer in the United States. Cancer 2017;123:5059-78. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

KW - cancer registries

KW - hepatitis

KW - liver

KW - population-based survival

UR - http://www.scopus.com/inward/record.url?scp=85037644100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037644100&partnerID=8YFLogxK

U2 - 10.1002/cncr.30820

DO - 10.1002/cncr.30820

M3 - Article

VL - 123

SP - 5059

EP - 5078

JO - Cancer

JF - Cancer

SN - 0008-543X

ER -